Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,181 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Factors associated with discrepancies in disease activity as assessed by SDAI and RAPID3 in patients with rheumatoid arthritis: Data from a multicentre observational study (T-FLAG).
Suzuki M, Asai S, Ohashi Y, Sobue Y, Ishikawa H, Takahashi N, Terabe K, Sato R, Kosugiyama H, Hasegawa J, Ohno Y, Sugiura T, Imagama S. Suzuki M, et al. Among authors: takahashi n. Mod Rheumatol. 2024 Dec 25;35(1):57-63. doi: 10.1093/mr/roae040. Mod Rheumatol. 2024. PMID: 38727542
Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients.
Takahashi N, Kojima T, Terabe K, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Fukaya N, Ishikawa H, Hayashi M, Tsuboi S, Kato D, Funahashi K, Matsubara H, Hattori Y, Hanabayashi M, Hirabara S, Yoshioka Y, Ishiguro N. Takahashi N, et al. Mod Rheumatol. 2013 Sep;23(5):904-12. doi: 10.1007/s10165-012-0760-4. Epub 2012 Sep 14. Mod Rheumatol. 2013. PMID: 22975734
Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.
Kojima T, Yabe Y, Kaneko A, Hirano Y, Ishikawa H, Hayashi M, Miyake H, Takagi H, Kato T, Terabe K, Wanatabe T, Tsuchiya H, Kida D, Shioura T, Funahashi K, Kato D, Matsubara H, Takahashi N, Hattori Y, Asai N, Ishiguro N. Kojima T, et al. Among authors: takahashi n. Mod Rheumatol. 2013 Sep;23(5):977-85. doi: 10.1007/s10165-012-0782-y. Epub 2012 Oct 26. Mod Rheumatol. 2013. PMID: 23099471
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity.
Takahashi N, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Fukaya N, Ishikawa H, Hayashi M, Tsuboi S, Kanayama Y, Kato D, Funahashi K, Matsubara H, Hattori Y, Hanabayashi M, Hirabara S, Terabe K, Yoshioka Y, Ishiguro N. Takahashi N, et al. Clin Rheumatol. 2014 Jan;33(1):39-47. doi: 10.1007/s10067-013-2392-2. Epub 2013 Sep 22. Clin Rheumatol. 2014. PMID: 24057092 Free PMC article.
Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies.
Hirabara S, Takahashi N, Fukaya N, Miyake H, Yabe Y, Kaneko A, Ito T, Oguchi T, Kida D, Hirano Y, Fujibayashi T, Sugiura F, Hayashi M, Funahashi K, Hanabayashi M, Asai S, Ishiguro N, Kojima T. Hirabara S, et al. Among authors: takahashi n. Clin Rheumatol. 2014 Sep;33(9):1247-54. doi: 10.1007/s10067-014-2711-2. Epub 2014 Jun 28. Clin Rheumatol. 2014. PMID: 24970596 Free PMC article.
Longterm retention rate and risk factor for discontinuation due to insufficient efficacy and adverse events in Japanese patients with rheumatoid arthritis receiving etanercept therapy.
Matsubara H, Kojima T, Kaneko A, Hirano Y, Ishikawa H, Hattori Y, Miyake H, Oguchi T, Takagi H, Yabe Y, Kato T, Ito T, Fukaya N, Kanayama Y, Shioura T, Hayashi M, Fujibayashi T, Takahashi N, Funahashi K, Kato D, Hanabayashi M, Terabe K, Ishiguro N. Matsubara H, et al. Among authors: takahashi n. J Rheumatol. 2014 Aug;41(8):1583-9. doi: 10.3899/jrheum.130901. Epub 2014 Jul 15. J Rheumatol. 2014. PMID: 25028370
Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.
Kojima T, Yabe Y, Kaneko A, Takahashi N, Funahashi K, Kato D, Hanabayashi M, Asai S, Hirabara S, Asai N, Hirano Y, Hayashi M, Miyake H, Kojima M, Ishiguro N. Kojima T, et al. Among authors: takahashi n. Rheumatology (Oxford). 2015 Jan;54(1):113-20. doi: 10.1093/rheumatology/keu302. Epub 2014 Aug 7. Rheumatology (Oxford). 2015. PMID: 25102861
Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
Kobayakawa T, Kojima T, Takahashi N, Hayashi M, Yabe Y, Kaneko A, Shioura T, Saito K, Hirano Y, Kanayama Y, Miyake H, Asai N, Funahashi K, Hirabara S, Hanabayashi M, Asai S, Ishiguro N. Kobayakawa T, et al. Among authors: takahashi n. Mod Rheumatol. 2015 Mar;25(2):251-6. doi: 10.3109/14397595.2014.953668. Epub 2014 Sep 11. Mod Rheumatol. 2015. PMID: 25211402
Use of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: a retrospective observational study based on data from a Japanese multicentre registry study.
Takahashi N, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Fukaya N, Hayashi M, Tsuboi S, Kanayama Y, Funahashi K, Hanabayashi M, Hirabara S, Asai S, Yoshioka Y, Ishiguro N. Takahashi N, et al. Rheumatology (Oxford). 2015 May;54(5):854-9. doi: 10.1093/rheumatology/keu418. Epub 2014 Oct 21. Rheumatology (Oxford). 2015. PMID: 25339638
6,181 results